{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:16:07Z","timestamp":1783386967407,"version":"3.54.6"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Science and Technology Fund","award":["232102310442"],"award-info":[{"award-number":["232102310442"]}]},{"name":"Henan Province Key Subjects of Clinical Pharmacy","award":["Henan Province Key Subjects of Clinical Pharmacy"],"award-info":[{"award-number":["Henan Province Key Subjects of Clinical Pharmacy"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06182-5","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:33:01Z","timestamp":1778643181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NAT10-mediated crosstalk between acetylation and PARylation enhances the function of PARP1 promoting primary resistance in esophageal cancer"],"prefix":"10.1007","volume":"83","author":[{"given":"Yake","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaocen","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3803-8464","authenticated-orcid":false,"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"6182_CR1","doi-asserted-by":"publisher","first-page":"1126536","DOI":"10.3389\/fonc.2023.1126536","volume":"13","author":"M Ohsawa","year":"2023","unstructured":"Ohsawa M et al (2023) Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. Front Oncol 13:1126536. https:\/\/doi.org\/10.3389\/fonc.2023.1126536","journal-title":"Front Oncol"},{"key":"6182_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1186\/s12885-020-07574-x","volume":"20","author":"T Kagami","year":"2020","unstructured":"Kagami T et al (2020) The first evidence for slfn11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer 20:1123. https:\/\/doi.org\/10.1186\/s12885-020-07574-x","journal-title":"BMC Cancer"},{"key":"6182_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25\u201339. https:\/\/doi.org\/10.1038\/s41577-019-0218-4","journal-title":"Nat Rev Immunol"},{"key":"6182_CR4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon M et al (2021) Determinants of response and intrinsic resistance to pd-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov 11:2168\u20132185. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0219","journal-title":"Cancer Discov"},{"key":"6182_CR5","doi-asserted-by":"publisher","first-page":"975986","DOI":"10.3389\/fimmu.2022.975986","volume":"13","author":"P Fang","year":"2022","unstructured":"Fang P et al (2022) Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. Front Immunol 13:975986. https:\/\/doi.org\/10.3389\/fimmu.2022.975986","journal-title":"Front Immunol"},{"key":"6182_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41467-023-37013-x","volume":"14","author":"X Li","year":"2023","unstructured":"Li X et al (2023) Deacetylation induced nuclear condensation of hp1gamma promotes multiple myeloma drug resistance. Nat Commun 14:1290. https:\/\/doi.org\/10.1038\/s41467-023-37013-x","journal-title":"Nat Commun"},{"key":"6182_CR7","doi-asserted-by":"publisher","first-page":"216364","DOI":"10.1016\/j.canlet.2023.216364","volume":"573","author":"F-F Zhuo","year":"2023","unstructured":"Zhuo F-F et al (2023) Lycorine promotes idh1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells. Cancer Lett 573:216364. https:\/\/doi.org\/10.1016\/j.canlet.2023.216364","journal-title":"Cancer Lett"},{"key":"6182_CR8","doi-asserted-by":"publisher","first-page":"e0096322","DOI":"10.1128\/spectrum.00963-22","volume":"10","author":"S Yu","year":"2022","unstructured":"Yu S et al (2022) Histone acetylation regulator gcn5 mediates drug resistance and virulence of candida glabrata. Microbiol Spectr 10:e0096322. https:\/\/doi.org\/10.1128\/spectrum.00963-22","journal-title":"Microbiol Spectr"},{"key":"6182_CR9","doi-asserted-by":"publisher","first-page":"101815","DOI":"10.1016\/j.tranon.2023.101815","volume":"39","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Acetylation and deacetylation of histone in adipocyte differentiation and the potential significance in cancer. Transl Oncol 39:101815. https:\/\/doi.org\/10.1016\/j.tranon.2023.101815","journal-title":"Transl Oncol"},{"key":"6182_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41392-021-00489-4","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) Nat10 promotes gastric cancer metastasis via n4-acetylated col5a1. Signal Transduct Target Ther 6:173. https:\/\/doi.org\/10.1038\/s41392-021-00489-4","journal-title":"Signal Transduct Target Ther"},{"key":"6182_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15252\/embr.201540505","volume":"17","author":"X Liu","year":"2016","unstructured":"Liu X et al (2016) Nat10 regulates p53 activation through acetylating p53 at k120 and ubiquitinating mdm2. EMBO Rep 17:349\u2013366. https:\/\/doi.org\/10.15252\/embr.201540505","journal-title":"EMBO Rep"},{"key":"6182_CR12","doi-asserted-by":"publisher","first-page":"112810","DOI":"10.1016\/j.celrep.2023.112810","volume":"42","author":"W Wei","year":"2023","unstructured":"Wei W et al (2023) Nat10-mediated ac4c trna modification promotes egfr mrna translation and gefitinib resistance in cancer. Cell Rep 42:112810. https:\/\/doi.org\/10.1016\/j.celrep.2023.112810","journal-title":"Cell Rep"},{"key":"6182_CR13","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41401-024-01306-8","volume":"45","author":"X-X Wang","year":"2024","unstructured":"Wang X-X (2024) Acetylcytidine modification of amotl1 by n-acetyltransferase 10 contributes to cardiac fibrotic expansion in mice after myocardial infarction. Acta Pharmacol Sin 45:1425\u20131437. https:\/\/doi.org\/10.1038\/s41401-024-01306-8","journal-title":"Acta Pharmacol Sin"},{"key":"6182_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/s12885-017-3570-4","volume":"17","author":"Q Li","year":"2017","unstructured":"Li Q et al (2017) Nat10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity. BMC Cancer 17:605. https:\/\/doi.org\/10.1186\/s12885-017-3570-4","journal-title":"BMC Cancer"},{"key":"6182_CR15","first-page":"256","volume":"10","author":"J Wu","year":"2018","unstructured":"Wu J et al (2018) Inhibition of n-acetyltransferase 10 using remodelin attenuates doxorubicin resistance by reversing the epithelial-mesenchymal transition in breast cancer. Am J Transl Res 10:256\u2013264","journal-title":"Am J Transl Res"},{"key":"6182_CR16","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1093\/nar\/gkaa130","volume":"48","author":"H-Y Liu","year":"2020","unstructured":"Liu H-Y et al (2020) Acetylation of morc2 by nat10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res 48:3638\u20133656. https:\/\/doi.org\/10.1093\/nar\/gkaa130","journal-title":"Nucleic Acids Res"},{"key":"6182_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.yexcr.2009.03.007","volume":"315","author":"Q Shen","year":"2009","unstructured":"Shen Q et al (2009) Nat10, a nucleolar protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. Exp Cell Res 315:1653\u20131667. https:\/\/doi.org\/10.1016\/j.yexcr.2009.03.007","journal-title":"Exp Cell Res"},{"key":"6182_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.brainresbull.2022.05.004","volume":"185","author":"X-F Guo","year":"2022","unstructured":"Guo X-F et al (2022) Elevation of n-acetyltransferase 10 in hippocampal neurons mediates depression- and anxiety-like behaviors. Brain Res Bull 185:91\u201398. https:\/\/doi.org\/10.1016\/j.brainresbull.2022.05.004","journal-title":"Brain Res Bull"},{"key":"6182_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","volume":"20","author":"T Narita","year":"2019","unstructured":"Narita T et al (2019) Functions and mechanisms of non-histone protein acetylation. Nat Rev Mol Cell Biol 20:156\u2013174. https:\/\/doi.org\/10.1038\/s41580-018-0081-3","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6182_CR20","doi-asserted-by":"publisher","first-page":"109988","DOI":"10.1016\/j.celrep.2021.109988","volume":"37","author":"K Shimizu","year":"2021","unstructured":"Shimizu K et al (2021) Interplay between protein acetylation and ubiquitination controls mcl1 protein stability. Cell Rep 37:109988. https:\/\/doi.org\/10.1016\/j.celrep.2021.109988","journal-title":"Cell Rep"},{"key":"6182_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"Ray Chaudhuri and Nussenzweig(","year":"2017","unstructured":"Ray Chaudhuri and Nussenzweig( (2017) The multifaceted roles of parp1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18:610\u2013621. https:\/\/doi.org\/10.1038\/nrm.2017.53","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6182_CR22","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.molcel.2022.03.034","volume":"82","author":"F Wang","year":"2022","unstructured":"Wang F et al (2022) Cytoplasmic parp1 links the genome instability to the inhibition of antiviral immunity through parylating cgas. Mol Cell 82:2032\u20132049. https:\/\/doi.org\/10.1016\/j.molcel.2022.03.034","journal-title":"Mol Cell"},{"key":"6182_CR23","doi-asserted-by":"publisher","first-page":"102651","DOI":"10.1016\/j.dnarep.2019.102651","volume":"81","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Parp-1 and its associated nucleases in DNA damage response. DNA Repair (Amst) 81:102651. https:\/\/doi.org\/10.1016\/j.dnarep.2019.102651","journal-title":"DNA Repair (Amst)"},{"key":"6182_CR24","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/nar\/gkz120","volume":"47","author":"EE Alemasova","year":"2019","unstructured":"Alemasova EE, Lavrik OI (2019) Poly(adp-ribosyl)ation by parp1: Reaction mechanism and regulatory proteins. Nucleic Acids Res 47:3811\u20133827. https:\/\/doi.org\/10.1093\/nar\/gkz120","journal-title":"Nucleic Acids Res"},{"key":"6182_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41556-022-00872-5","volume":"24","author":"H Fu","year":"2022","unstructured":"Fu H et al (2022) Poly(adp-ribosylation) of p-tefb by parp1 disrupts phase separation to inhibit global transcription after DNA damage. Nat Cell Biol 24:513\u2013525. https:\/\/doi.org\/10.1038\/s41556-022-00872-5","journal-title":"Nat Cell Biol"},{"key":"6182_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10565-022-09739-9","volume":"39","author":"JM Reber","year":"2023","unstructured":"Reber JM et al (2023) Parp1 and xrcc1 exhibit a reciprocal relationship in genotoxic stress response. Cell Biol Toxicol 39:345\u2013364. https:\/\/doi.org\/10.1007\/s10565-022-09739-9","journal-title":"Cell Biol Toxicol"},{"key":"6182_CR27","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1093\/nar\/gku298","volume":"42","author":"A Soni","year":"2014","unstructured":"Soni A et al (2014) Requirement for parp-1 and DNA ligases 1 or 3 but not of xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res 42:6380\u20136392. https:\/\/doi.org\/10.1093\/nar\/gku298","journal-title":"Nucleic Acids Res"},{"key":"6182_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.29271\/jcpsp.2021.03.326","volume":"31","author":"I Karadag","year":"2021","unstructured":"Karadag I et al (2021) Cross or flot in distal esophageal and gastroesophageal cancer. J Coll Physicians Surg Pak 31:326\u2013329. https:\/\/doi.org\/10.29271\/jcpsp.2021.03.326","journal-title":"J Coll Physicians Surg Pak"},{"key":"6182_CR29","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1111\/1759-7714.13570","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T et al (2020) Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer ec109 cell through wnt\/beta-catenin signaling pathway. Thorac Cancer 11:2316\u20132324. https:\/\/doi.org\/10.1111\/1759-7714.13570","journal-title":"Thorac Cancer"},{"key":"6182_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-023-01780-4","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y et al (2023) Aberrant m5c hypermethylation mediates intrinsic resistance to gefitinib through nsun2\/ybx1\/qsox1 axis in egfr-mutant non-small-cell lung cancer. Mol Cancer 22:81. https:\/\/doi.org\/10.1186\/s12943-023-01780-4","journal-title":"Mol Cancer"},{"key":"6182_CR31","doi-asserted-by":"publisher","first-page":"100745","DOI":"10.1016\/j.esmoop.2022.100745","volume":"8","author":"D Ciardiello","year":"2023","unstructured":"Ciardiello D et al (2023) Targeting kras(g12c) in colorectal cancer: The beginning of a new era. ESMO Open 8:100745. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100745","journal-title":"ESMO Open"},{"key":"6182_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.17305\/bjbms.2022.8286","volume":"23","author":"R Wang","year":"2023","unstructured":"Wang R et al (2023) Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis. Biomol Biomed 23:198\u2013208. https:\/\/doi.org\/10.17305\/bjbms.2022.8286","journal-title":"Biomol Biomed"},{"issue":"1514","key":"6182_CR33","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.3390\/cancers15143642","volume":"15","author":"S Dilmac","year":"2023","unstructured":"Dilmac S, Ozpolat B (2023) Mechanisms of parp-inhibitor-resistance in brca-mutated breast cancer and new therapeutic approaches. Cancers (Basel) 1514:3642. https:\/\/doi.org\/10.3390\/cancers15143642","journal-title":"Cancers (Basel)"},{"key":"6182_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1272\/jnms.JNMS.2020_87-508","volume":"87","author":"Asano(","year":"2020","unstructured":"Asano( (2020) Drug resistance in cancer therapy and the role of epigenetics. J Nippon Med Sch 87:244\u2013251. https:\/\/doi.org\/10.1272\/jnms.JNMS.2020_87-508","journal-title":"J Nippon Med Sch"},{"key":"6182_CR35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2217\/fmb-2019-0343","volume":"15","author":"S Su","year":"2020","unstructured":"Su S et al (2020) Histone acetylation\/deacetylation in candida albicans and their potential as antifungal targets. Future Microbiol 15:1075\u20131090. https:\/\/doi.org\/10.2217\/fmb-2019-0343","journal-title":"Future Microbiol"},{"key":"6182_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13205-021-03038-6","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V et al (2022) Pleiotropic role of parp1: An overview. Biotech 12:3. https:\/\/doi.org\/10.1007\/s13205-021-03038-6","journal-title":"Biotech"},{"key":"6182_CR37","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.1093\/nar\/gkac948","volume":"50","author":"T Mosler","year":"2022","unstructured":"Mosler T et al (2022) Parp1 proximity proteomics reveals interaction partners at stressed replication forks. Nucleic Acids Res 50:11600\u201311618. https:\/\/doi.org\/10.1093\/nar\/gkac948","journal-title":"Nucleic Acids Res"},{"key":"6182_CR38","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J et al (2012) Trapping of parp1 and parp2 by clinical parp inhibitors. Cancer Res 72:5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753","journal-title":"Cancer Res"},{"key":"6182_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T et al (2019) Maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"key":"6182_CR40","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S et al (2021) Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a brca mutation (solo1\/gog 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 22:1721\u20131731. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3","journal-title":"Lancet Oncol"},{"key":"6182_CR41","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL et al (2022) Overall survival results from the polo trial: A phase iii study of active maintenance olaparib versus placebo for germline brca-mutated metastatic pancreatic cancer. J Clin Oncol 40:3929\u20133939. https:\/\/doi.org\/10.1200\/JCO.21.01604","journal-title":"J Clin Oncol"},{"key":"6182_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ygyno.2021.11.011","volume":"164","author":"C Moya-Alarcon","year":"2022","unstructured":"Moya-Alarcon C et al (2022) Olaparib as first line in brca-mutated advanced ovarian carcinoma: Is it cost-effective in spain? Gynecol Oncol 164:406\u2013414. https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.011","journal-title":"Gynecol Oncol"},{"key":"6182_CR43","doi-asserted-by":"publisher","first-page":"e0144287","DOI":"10.1371\/journal.pone.0144287","volume":"10","author":"L Verdone","year":"2015","unstructured":"Verdone L et al (2015) Poly(adp-ribosyl)ation affects histone acetylation and transcription. PLoS ONE 10:e0144287. https:\/\/doi.org\/10.1371\/journal.pone.0144287","journal-title":"PLoS ONE"},{"key":"6182_CR44","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.dnarep.2024.103711","volume":"140","author":"C \u00d6zdemir","year":"2024","unstructured":"\u00d6zdemir C et al (2024) Particular marks: Histone adp-ribosylation and the DNA damage response. DNA Repair (Amst) 140:103711. https:\/\/doi.org\/10.1016\/j.dnarep.2024.103711","journal-title":"DNA Repair (Amst)"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06182-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06182-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06182-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:56:41Z","timestamp":1783385801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06182-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6182"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06182-5","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to the Ethic Requirements of Institutional Animal Care and Use Committee (XXMU2020070) at Xinxiang Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}